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Abstract
Background: Chromosome 17q21.31 microdeletion syndrome is a multisystem genomic disorder caused by a
recurrent 600-kb-long deletion, or haploinsufficiency of the chromatin modifier gene KANSL1, which maps to that
region. Patients with KANSL1 intragenic mutations have been reported to display the major clinical features of
17q21.31 microdeletion syndrome. However, they did not exhibit the full clinical spectrum of this disorder, which
might indicate that an additional gene or genes, located in the 17q21.31 locus, might also be involved in the
syndrome’s phenotype.
Methods: Conventional and molecular karyotypes were performed on a female patient with intellectual disability,
agenesis of the corpus callosum, heart defects, hydronephrosis, hypotonia, pigmentary skin anomalies and facial
dysmorphic features. FISH analysis was conducted for chromosomal breakpoint localization. qRT-PCR was applied
for the comparative gene expression of KANSL1 gene in the patient and a control group.
Results: Herein, we present the first report of disruption and haploinsufficiency of the KANSL1 gene, secondary to a
t(1;17)(q12;q21)dn chromosomal translocation in a girl that also carried a de novo ~289-kb deletion on 16p11.2. KANSL1
gene expression studies and comparative clinical analysis of patients with 17q21.31 deletions and intragenic KANSL1
gene defects indicate that KANSL1 dysfunction is associated with the full spectrum of the 17q21.31 microdeletion
syndrome, which includes characteristic facial features, hypotonia, intellectual disability, and structural defects of the
brain, heart and genitourinary system, as well as, musculoskeletal and neuroectodermal anomalies. Moreover, we
provide further evidence for the overlapping clinical phenotype of this condition with the cardio-facio-cutaneous (CFC)
syndrome.
Conclusions: KANSL1 gene haploinsufficiency is necessary and sufficient to cause the full spectrum of the 17q21.31
microdeletion syndrome. We hypothesize that the KANSL1 gene might have an effect on the Ras/mitogen-activated
protein kinase (MAPK) pathway activity, which is known to be deregulated in the CFC syndrome. This pathway has a
crucial role in the development of the heart and craniofacial morphology, as well as the skin, eye, brain and
musculoskeletal systems.
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Background
The 17q21.31 microdeletion syndrome (del17q21.31), also
known as the Koolen-De Vries Syndrome, is characterized
by distinctive facial features, hypotonia, intellectual
disability and friendly/amiable behavior [1, 2]. Over 50 %
of the cases also present with structural defects of the
brain (agenesis of the corpus callosum, ventricle dilata-
tion), heart (aortic and/or pulmonary stenosis, ventricular
and atrial septal defects) and/or genitourinary system.
Additional signs include musculoskeletal features and hair,
dental and pigmentary skin anomalies [2–6] that, in some
cases, resemble those seen in the cardio-facio-cutaneous
(CFC) syndrome.
The critical deleted region of the del17q21.31 syn-
drome was initially defined as a 424-kb segment [2], and
later narrowed down to 160–274 kb containing MAPT,
STH and KANSL1 genes [5, 7]. Recent reports of small
atypical deletions and heterozygous intragenic mutations
in KANSL1 demonstrated that haploinsufficiency of this
gene is responsible for the major clinical signs of the
syndrome [8, 9]. However, with the exception of a
ventricular septal defect that spontaneously corrected,
structural defects were not present in patients with
intragenic KANSL1 mutations. Therefore, it is plausible
that additional genes at the 17q21.31 locus might
account for the severity of the clinical phenotype of the
del17q21.31 syndrome.
Analysis of apparently balanced chromosomal abnor-
malities associated with developmental disorders has
been a successful approach to gene discovery, as the
abnormal associated phenotype can be caused by hidden
genomic defects at the molecular level [10, 11]. Herein,
we report on the first patient to be described to have a
de novo (1;17) translocation that truncates the KANSL1
gene. In addition, we also reviewed the phenotype of
cases with 17q21.31 microdeletions and KANSL1 in-
tragenic defects, in an attempt to further define the
full clinical spectrum of the syndrome and understand




The proband for our study was a girl born after a 36-
week gestation complicated by fetal hydrocephaly. She
weighed 1860 g, measured 45.5 cm and had a head
circumference (OFC) of 30.6 cm. She presented with
facial dysmorphic features, hypotonia, dilatation of cere-
bral ventricles, agenesis of the corpus callosum, aortic
stenosis, bicuspid aorta and bilateral hydronephrosis.
During the neonatal period she had severe feeding diffi-
culties and frequent urinary infections that were caused
by vesico-ureteral reflux and required surgical treatment.
Her psychomotor milestones were delayed. She walked
at 4 years, had language difficulties and needed special
education. Facial characteristics are shown in Fig. 1a.
She had a long face, short and upslanting palpebral
fissures, hypertelorism, epicanthal folds, ptosis of the
eyelids, iris heterochromia, broad nasal bridge, bulbous
nose with thick, hypoplastic nares, long chin and
absence of permanent lateral incisors. Her hair was
coarse and thick. She also presented numerous nevi, café
au lait spots and hypopigmented areas. At the age of
13 years, she showed severe thoracic kyphosis, moder-
ate/severe intellectual disability, speech and deficit atten-
tion disorders, and a compulsive appetite that required
strict diet control. Continuous cardiac and renal evalua-
tions demonstrated mild pulmonary stenosis, peripheral
cyanosis, vasomotor liability and increased size of the
left ventricle, as well as a chronic renal disease with
hypertension and hyperproteinuria. At her last examin-
ation (19 years of age) her weight, height and OFC were
at the 90th, 10th and 50th percentiles, respectively.
The Ethics Committee at our institution (Comité Ético
de Investigación Clínica de Navarra—CEIC) approved
Fig. 1 Individual with t(1;17)dn. a Facial features of the patient. b G-banding partial karyotype showing the apparently balanced translocation
between chromosomes 1 and 17
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this study. Written informed consent was obtained from
the patient’s parents.
Conventional and molecular karyotype
Metaphase chromosomes were obtained from cultured
peripheral lymphocytes of our patient and her parents,
and a standard GTL-banding karyotype was performed
for conventional cytogenetic analysis. Genomic DNA
was extracted from peripheral blood cells of the patient
for array-based Comparative Genomic Hybridization
(aCGH) studies (Agilent Technologies). The patient was
studied with a 105-K platform and a mixture of 1 μg test
Cy5-labeled DNA and 1 μg male reference (Promega)
Cy3-labeled DNA was used in the hybridization. The
software Genomic Workbench 7.0 was used for the bio-
informatic analysis of the copy number variants (CNVs).
An altered copy number of DNA was considered when a
region contained a minimum of five consecutive probes.
Locations are based on hg18/NCBI mapview build 36.
Fluorescence in situ hybridization (FISH)
Metaphase spreads were obtained from phytohaemagglutinin-
stimulated peripheral blood lymphocytes of the patient and
both parents. Bacterial artificial chromosome (BAC) clones
were selected from the Centro de Regulación Genómica
Genome Browser [12]. Plasmid DNA was extracted from
clones using QIAprep Spin Miniprep Kit (Qiagen) and la-
beled with Spectrum Orange dUTP (SpO) or Spectrum
Green dUTP (SpG) using the Nick Translation Reagent Kit
(Abbott Molecular Inc.). FISH experiments were carried
out according to standard procedures. The slides were
examined using a Nikon Eclipse E400 with appropriate
filters for Spectrum Orange, Spectrum Green and the UV
Filter for the DAPI nuclear counterstain. The signals were
recorded with a CCD camera and processed by ISIS v5.1
fluorescence imaging system (MetaSystems).
Gene expression assay
Quantitative reverse-transcription polymerase chain
reaction (qRT-PCR) was performed with RNA extracted
from the patient and five control individuals. Total RNA
was isolated from whole blood using the QIAamp RNA
Blood Mini kit (Qiagen), following the manufacturer’s
instructions. cDNA synthesis was performed with 1 μg
of RNA using a TaqMan Reverse Transcription Reagents
kit (Invitrogen-Life Technologies) in a total volume of
50 μL. Primer and probe mixtures for KANSL1
(Hs00393805_m1, localized at exon boundary 7–8,
NM_001193465.1) and the endogenous gene GAPDH
(Hs99999905_m1, exon location 3, NM_002046.3) were
supplied by Applied Biosystems. The PCR reactions were
run in a 7300 Real Time PCR System (Applied Bio-
systems). All samples of cDNA (40 ng per well) were
run in triplicate in 20 μL reaction volumes. The
thermal cycling parameters were the standard condi-
tions of the Real Time PCR System. Relative differ-
ences in transcript levels were quantified with the
ΔΔCt method and data are reported as the fold-
change in expression of the proband relative to the
mean ± SEM of the control group.
Results
Balanced de novo translocation (1;17)
The patient’s karyotype analysis revealed the presence of
an apparently balanced de novo translocation, designated
46,XX,t(1;17)(q12;q21)dn (Fig. 1b).
De novo microdeletion on the 16p11.2 atypical/distal
region
The aCGH study detected an ~289-kb deletion on the
16p11.2 atypical/distal region, flanking the recurrent
microdeletion/duplication locus (Fig. 2a). No genomic
imbalances were observed at translocation breakpoints
or other genomic regions. Additional FISH analysis
using the RP11-264B17 BAC probe confirmed the de
novo origin of the 16p11.2 distal deletion in the patient
(Fig. 2b). Combining the results of the GTL-banding,
FISH and aCGH experiments, we concluded that the
patient had the karyotype 46,XX,t(1;17)(q12;q21)dn.ish
del(16)(q11.2q11.2)(RP11-264B17-). arr[hg18] 16q11.2
(28,732,295-29,021,443) × 1 dn.
KANSL1 disruption and reduced gene expression
FISH analysis, using the overlapping BAC clones
RP11-782E01 and RP11-86C01 on 17q21.31, revealed
hybridization signals on both derivative chromosomes
(1 and 17). Additional studies with flanking probes
RP11-368D10 and RP11-259G18 showed one signal on
der(17) and one on der(1) chromosomes, respectively.
These results indicated that RP11-782E01 and RP11-
86C01 BAC probes spanned the translocation break-
point, placing the breakpoint within a 65.6-kb region
of overlap at the 17q21.31 band, which would disrupt
the KANSL1 gene (Fig. 3). This overlapping region
contains a small segmental duplication, which might
have contributed to a non-allelic homologous recom-
bination event, favoring the chromosome disruption at
this point.
To determine how KANSL1 gene expression was af-
fected by the de novo translocation, transcript levels
were assessed by qRT-PCR. The relative differences in
transcript levels corresponding to KANSL1 in the patient
were half of those observed in controls, correlating with
the finding of the KANSL1 gene disruption in one
chromosome (Fig. 4).
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Discussion
We present the first report of haploinsufficiency of the
KANSL1 gene caused by gene interruption, secondary to
a de novo (1;17)(q12;q21) chromosomal translocation.
The patient, who also carries an ~289-kb deletion flank-
ing the recurrent 16p11.2 region, shows the complete
phenotype of the 17q21.31 microdeletion syndrome,
including characteristic facial features, hypotonia, intel-
lectual disability, and structural defects of the brain,
heart and genitourinary system, as well as musculoskel-
etal and neuroectodermal anomalies.
To analyze the association of the KANSL1 gene
disruption with the patient’s phenotype, we compared
the frequencies of signs previously described in cases
with small (424 kb) and large (502–800 kb) 17q21.31
deletions with patients carrying a KANSL1 gene defect,
including the present case. As shown in Table 1, the se-
verity of clinical presentation of the 17q21.31 syndrome
does not correlate with the size of the deletion. More-
over, our patient presented with most of the structural
defects, facial features and cognitive characteristics pre-
viously described in patients with that syndrome. It
could be argued, however, that her phenotype might be
attributable, at least partially, to the presence of the
16p11.2 microdeletion. This deletion, which overlaps
with that described in the 16p11.2 deletion syndrome
(220 kb), includes nine genes (ATXN2L, TUFM, SH2B1,
ATP2A1, RABEP2, CD19, NFATC2IP, SPNS1 and LAT).
Interestingly, SH2B1 is known to be involved in leptin
and insulin signaling [13] and has been reported as a
predisposing factor for obesity [14]. In agreement with
this hypothesis, our patient showed a compulsive appe-
tite with difficulty in managing her weight that required
strict diet control. Functions of other genes included in
the 16p11.2-deleted region are currently unknown, but
they do not seem to make a clear and significant contri-
bution to the phenotype. Some authors have described
cases with distal 16p11.2 deletion showing developmen-
tal delay, behavioral problems and unusual facial morph-
ology. Although detailed clinical information may not
have been available for most patients participating in
large study cohorts, structural birth defects have not
been previously observed associated with this genomic
imbalance. Therefore, we conclude that although we can
not rule out that the 289-kb microdeletion on distal
16p11.2 might contribute to the severity of the intellec-
tual disability and/or the behavioral problems in our pa-
tient, there is currently no evidence indicating that other
clinical manifestations can be attributable to the pres-
ence of this genomic imbalance. On the contrary, her fa-
cial appearance and the specific brain (agenesis of the
corpus callosum), cardiac (valvulo-septal defects) and
Fig. 2 aCGH and FISH experiments on 16p11.2. a A detail of the patient’s aCGH analysis showing a ~289-kb deletion on the chromosome
16p11.2 distal region. b FISH experiments on the patient and both parents using RP11-264B17 (SpO) BAC clone. Only one signal was observed on
16p11.2 in the patient, confirming the deletion found in aCGH. Two hybridization signals were observed in each parent, indicating the de novo
origin of the deletion. Location of RP11-264B17 probe based on hg18: 28786266–28936684
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renal defects (dilation of the renal system) were very
similar to those previously described in cases with
17q21.31 microdeletion syndrome.
The wide range of defects affecting the skin, hair, irises
and teeth present in our patient are of particular interest
as they indicate a role of the KANSL1 gene in neuroec-
todermal developmental processes. Additionally, these
neurocutaneous signs, in conjunction with the muscu-
loskeletal and cardiac manifestations, including the
myocardiopathy, overlap with the phenotype of CFC
syndrome. This disorder belongs to a clinically defined
group of genetic syndromes caused by germline muta-
tions in genes that encode for components or regulators
of the Ras/MAPK pathway, generically known as RASo-
pathies [15]. The phenotypic similarity between the
17q21.31 deletion syndrome and some RASopathies
might be indicative of the possible influence of the
KANSL1 gene on the Ras-MAPK pathway activity, which
Fig. 4 Quantification of KANSL1 gene expression levels by qRT-PCR.
The expression level of KANSL1 gene on the patient bearing the
t(1;17) (grey bar) was half that observed in the control group
(black bar)
Fig. 3 Mapping of the breakpoint on chromosome 17. Genomic context for the 17q21.31 breakpoint studied by FISH showing the genes
(different transcript variants represented) and segmental duplications mapping in the region, and the position of the FISH probes RP11-368D10
(41315374–41484448), RP11-782E01 (41339059–41559177), RP11-86C01 (41493577–41644115) and RP11-259G18 (41559185–41734024).
Coordinates are given according to the human reference sequence hg18 (adapted from the UCSC genome browser [20]). RP11-368D10 BAC
probe gives red signal on chromosomes 17 and der(17). RP11-782E01 probe gives red signal on chromosomes 17, der(17) and der(1), overlapping
the translocation breakpoint. RP11-86C01 probe gives signal on chromosomes 17, der(1) and der(17), overlapping the translocation breakpoint on
KANSL1 gene. RP11-259G18 BAC probe gives signal on chromosomes 1 and der(1). RP11-715D19 probe (SpG) has been used as a guide on
chromosomes 1 and der(17). The blue box represents the putative region for the KANSL1 gene disruption
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Age (years) at last observation 3 14 2, 11/12 13 17
Sex 9 M/13 F 6 M/4 F F F F F F
Growth
Intrauterine growth retardation 27 10 + - - - -
Short stature 18 30 -
Microcephaly 5 - -
Neurological features
Hypotonia 96 80 + + + + +
Failure to thrive 40 + + + + +
Developmental delay/intellectual disability 100 100 + + + + +
Speech disorder 50 + + +
Seizures 60 - - - - +
Engaging or amiable personality 89 50 + + + + -
Behavioral disorder 30 +
Facial dysmorphic features
Broad forehead 68 40 + + + +
Long face 74 70 - + +
Short palpebral fissures 36 10 - + +
Upslanting palpebral fissures 68 70 + + + + +
Ptosis 50 - - - - - +
Epicanthal folds 68 10 + + + + +
“Pear” shaped nose 82 40 + + + + +
Large nasal bridge 30 + + +
Bulbous nasal tip 95 90 + + +
Long philtrum 10 + + +
Cleft palate 9 - - - - - -
High/narrow palate 50 10 -
Large/prominent ears 59 80 + + -
Broad chin 42 10 + + + - +
Ophthalmological features
Hypermetropia 36 - - + -
Strabismo 45 10 - + -
Iris color defects (pale/heterochromia) 45 - - - - - +
Congenital structural defects
Brain 38 60 - - - - +
Heart defects 27 30 - - - + +
Renal & urologic anomalies 32 50 - - - - +
Criptorchidism 78 67
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has a crucial role in the development of the heart and
craniofacial morphology, as well as the skin, eye, brain
and musculoskeletal systems.
KANSL1 is a nuclear protein identified as a member
of the non-specific lethal (NSL) complex. This histone
acetyltransferase (HAT) complex also includes MOF,
encoded by KAT8, and exerts its influence on gene ex-
pression through the acetylation of histone H4, mainly
H4K16 [16]. KANSL1 is necessary and sufficient for
regulating MOF acetyltransferase activity on nucleo-
some H4. Moreover, it is also required for the specific
acetylation of p53 on K120, which is crucial for the
differential and optimal transcription activation of
p53 target genes, both in vivo and in vitro [17].
BTG2 (B-cell translocation gene 2) is an early
growth response gene whose promoter contains p53-
binding sites that is strongly regulated by p53 [18].
Interestingly, BTG2 is one of the mediators of the
p53-dependent inhibition of H-Ras activity, which is
involved in a variety of biological processes including
cell growth, development, differentiation, senescence
and cell death. This gene binds H-Ras (G12V) and
represses its activity by reducing its GTP loading
state, which, in turn, activates the Ras/MAPK signal-
ing cascade and causes a reduction in the expression
of a large number of downstream molecules [19].
Therefore, it is plausible that dysfunction of KANSL1
might perturb the activity of p53 transcription target
genes, such as BTG2, producing an aberrant regula-
tion of important downstream cascades of Ras. This
mechanism could explain the overlapping phenotypic
features observed in the KANSL1 haploinsufficiency
phenotype and the RASopathies. Additional clinical
and experimental studies will be needed to evaluate
this hypothesis and further understand the molecular
mechanisms associated with deleterious KANSL1 alleles.
Conclusions
We present the first report of haploinsufficiency of the
KANSL1 gene caused by gene interruption, secondary
to a chromosomal translocation, associated with the
complete phenotype of the 17q21.31 microdeletion syn-
drome, including brain, cardiac and renal structural
defects not previously described in patients bearing
KANSL1 point mutations. This further demonstrates
that dysfunction of the KANSL1 gene is necessary and
sufficient to cause the full clinical spectrum of this syn-
drome. We also hypothesize that the KANSL1 gene
might have an effect on the Ras/MAPK pathway activ-
ity, which is known to be deregulated in the CFC
syndrome.
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Table 1 Summary of clinical signs observed in patients with del17q21.31 (classical and larger sizes), KANSL1 mutations and KANSL1
disruption (Continued)
Musculoskeletal features
Slender fingers/hands 61 20 +
Dislocation of the hip 27 30 - + - + -
Joint laxity 30 + + + + +
Pectus deformity 23 10 - - - - -
Kiphosis/Scoliosis 36 30 - - - - +
Skin, hair, teeth
Abnormal hair texture 55 30 + + + + +
Skin pigmentary abnormalities 50 - - - + +
Hipodontia 20 +
aBased on description of 10 individuals with large 17q21.31 deletions [3–5, 21–23]
“+”, presence of the clinical sign; “-”, absence of the clinical sign; “blank”, not assessed; “M”, male; “F”, female
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